BillionToOne Is Solving One of Biotech’s Hardest Problems

Core Mission & Technology

• Billion to One is a molecular diagnostics company that detects circulating cell-free DNA (cfDNA) from blood samples, including fetal and tumor DNA.
• The company's proprietary "Billion-to-One" methodology solves the "needle in a haystack" problem by identifying single base-pair variations among 3 billion base pairs.
• Unlike traditional methods that amplify all DNA and introduce noise, the company adds synthetic DNA (QCTs) before amplification to measure and mathematically remove sequencing errors.
• This approach converts complex biological detection challenges into solvable mathematical problems, enabling the detection of rare signals previously impossible to isolate.

Business Traction & Scale

• The company went public late last year with a valuation exceeding $4 billion.
• Current operational capacity processes over 600,000 tests annually, capturing approximately 20% of the relevant market share.
• A 2022 facility upgrade, incorporating AI and computer vision for "Accessioning in 60 Seconds," enables scaling toward 2 million tests per year (potentially covering 1 in 3 babies).
• Commercial adoption began with one physician user two months post-launch; the team pivoted to a direct-to-consumer marketing strategy to drive patient demand, eventually achieving a 1-in-5 success rate in patient-to-physician conversions.

Strategic Product Roadmap

• Step 1 (Completed): Universal prenatal genetic screening for expecting mothers, replacing invasive amniocentesis for high-risk pregnancies.
• Step 2 (Current): Commercial launch of "North Star Select," an ultra-sensitive liquid biopsy for late-stage cancer (minimal residual disease) to guide immunotherapy decisions.
• Step 3 (Upcoming): Launch of an ultra-sensitive test for stage 1–2 cancer patients to detect microscopic tumor residue after curative-intent surgery, preventing recurrence in the ~20% of patients currently undetectable by scans.
• Step 4 (Long-term): Development of population-wide early detection screening to identify stage 1 cancers in healthy individuals before symptoms arise, described by founders as the "holy grail of cancer detection."

Founding History & Execution

• Founded by Ph.D. students Oguzhan and David, who started in 2017 with only a shared lab bench and $300,000 in seed funding.
• The founders bridged the gap between chemistry and bioinformatics, an interdisciplinary requirement necessary to solve the specific noise-removal challenges of cfDNA.
• Early fundraising was significantly difficult, with the first $300,000 taking six months to raise; suppliers initially refused to sell equipment due to lack of corporate banking infrastructure.
• The company successfully launched its first test in under two years, proving accuracy and gaining approval in a radical timeframe.

Organizational Structure & Culture

• The company employs an "interdisciplinary" hiring model, seeking scientists capable of managing both experimental chemistry and computational data analysis within small, autonomous teams.
• Organizational hierarchy is flattened; principal investigators and small research groups (2–3 associates) report directly to the founders, eliminating bureaucracy to accelerate iteration cycles by an order of magnitude.
• Employee retention remains high despite the recent IPO; the leadership explicitly frames the company as a high-difficulty challenge, attracting talent motivated by the "pressure is a privilege" philosophy.

Clinical Impact & Patient Outcomes

• A specific case study involved a patient in their 40s with metastatic colorectal cancer deemed terminal; the test identified microsatellite instability in circulating tumor DNA, qualifying the patient for immunotherapy.
• The patient experienced a dramatic response described as "melting away" cancer, despite failing previous tissue biopsy tests due to tumor heterogeneity.
• This success has led to a referral pattern where the treating physician now sends blood tests from nearly all cancer patients.

Future Outlook & Strategic Rationale

• The step-by-step market entry (prenatal → late-stage cancer → early-stage detection) was a capital-intensive necessity, allowing the company to fund R&D without raising over $1 billion upfront for early detection.
• The technology is designed to eventually screen the general population annually, potentially making the largest dent in cancer mortality in the last 100 years.
• Founders acknowledge that achieving early detection requires first solving the difficult but capital-efficient prenatal market to generate revenue and resources.